Trial · NCT07894289
Examining the Role of Sensitivity to Uncertain Threat and Alcohol Response in Risk for Alcohol Use Disorder Following Sexual Assault in College Women
NCT07894289, Early phase 1, Not yet recruiting, Ohio State University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Examining the Role of Sensitivity to Uncertain Threat and Alcohol Response in Risk for Alcohol Use Disorder Following Sexual Assault in College Women. Trials, record NCT07894289. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07894289
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Examining the Role of Sensitivity to Uncertain Threat and Alcohol Response in Risk for Alcohol Use Disorder Following Sexual Assault in College Women
- NCT number
- NCT07894289
- Status
- Not yet recruiting
- Phases
- Early phase 1
- Enrollment
- 220 participants, estimated
- Lead sponsor
- Ohio State University
- Conditions
- Sexual Assault, Alcohol Intoxication
- Interventions
- Alcohol, Placebo
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Startle eyeblink potentiation during the threat task | Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3) | Startle eyeblink potentiation will be collected during the NPU threat task that is administered at all three lab sessions. Startle is a cross-species index of aversive reactivity. |
| Primary | Subjective affective response to alcohol in the lab | At the Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart. | Participants will complete the Profile of Mood States (POMS) throughout the placebo and alcohol administration protocols. The Profile of Mood States Anxiety subscale consists of 9 items, with each item rated from 0 (not at all) to 4 (extremely), resulting in a total score ranging from 0 to 36. Higher scores indicate greater subjective anxiety, while lower scores indicate less subjective anxiety. The Anxiety subscale will serve as the primary measure of subjective anxiety and will be compared between the placebo and alcohol sessions. |
| Primary | Subjective effects of alcohol in the lab | At the Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart. | Participants will rate the degree to which they 'feel', 'like', and 'want more' of the infused substance on a visual analogue scale ranging from 0 ('not at all') to 100 ('extremely'). The 'like' and 'want more' scales will serve as the primary measures of drug liking and drug wanting, respectively. |
| Primary | Ecological momentary assessment (EMA) of affective response to alcohol in the real world | Assessed daily for 21-days | Up to five times per day, participants will complete ecological momentary assessments (EMA) of their current anxiety, distress, and other mood states. Participants will rate each emotion on a 0-5 scale, where 0 = not at all and 5 = extremely. Affect will be assessed during periods of sobriety and intoxication. |
| Primary | Transdermal alcohol concentration (TAC) | Assessed daily for 21-days | Participants' TAC will provide an objective estimate of alcohol consumption. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01AA032115 | Examining the Role of Sensitivity to Uncertain Threat and Alcohol Response in Risk for AUD following Sexual Assault | Gorka, Stephanie; Weafer, Jessica J | OHIO STATE UNIVERSITY | NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM | 2026 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07894289
GET https://conductscience.org/api/trials/v1/NCT07894289/registered